Initial decrease in odds for long COVID seen after first vaccine dose with evidence suggesting sustained improvement after second dose<\/p>\n<\/h3>\n
<\/b><\/p>\n
<\/b><\/p>\n
MONDAY, May 23, 2022 (HealthDay News) — For adults who test positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), COVID-19 vaccination after infection is associated with a reduced likelihood of long COVID symptoms, according to a study published online May 18 in The BMJ<\/em>.<\/p>\n Daniel Ayoubkhani, from the Office for National Statistics in Newport, England, and colleagues conducted an observational cohort study to estimate the associations between COVID-19 vaccination and long COVID symptoms in adults with SARS-CoV-2 infection before vaccination. Data were included for 28,356 participants aged 18 to 69 years who received at least one dose of vaccine after testing positive for SARS-CoV-2. Patients were followed for at least 12 weeks after infection during the period Feb. 3 to Sept. 5, 2021.<\/p>\n The researchers found that during follow-up, 23.7 percent of participants reported long COVID symptoms of any severity at least once. A first vaccine dose was associated with an initial decrease of 12.8 percent in the odds of long COVID, with subsequent data compatible with increases and decreases in the trajectory. A second vaccine dose was associated with an initial decrease of 8.8 percent in the odds of long COVID, followed by a subsequent decrease of 0.8 percent per week. There was no heterogeneity in the associations between vaccination and long COVID by confounding variables, including sociodemographic characteristics, health status, and vaccine type.<\/p>\n “Our results suggest that vaccination of people previously infected may be associated with a reduction in the burden of long COVID on population health, at least in the first few months after vaccination,” the authors write.<\/p>\n Abstract\/Full Text<\/a><\/p>\n